Glassman Wealth Services Ionis Pharmaceuticals Inc Transaction History

Glassman Wealth Services

18 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2023 Feb 09, 2024	SELL	$43.39 - $51.63 $2,299 - $2,736	-53 Reduced 7.17%	686 $34,000
Q2 2023 Aug 08, 2023	BUY	$34.73 - $43.33 $69 - $86	2 Added 0.27%	739 $30,000
Q1 2023 May 04, 2023	BUY	$33.58 - $41.2 $134 - $164	4 Added 0.55%	737 $26,000
Q4 2022 Feb 06, 2023	SELL	$37.12 - $46.52 $222 - $279	-6 Reduced 0.81%	733 $27,000
Q2 2022 Aug 04, 2022	SELL	$31.71 - $43.0 $2,631 - $3,569	-83 Reduced 10.1%	739 $27,000
Q1 2022 Aug 23, 2022	BUY	$29.88 - $37.04 $4,213 - $5,222	141 Added 20.7%	822 $30,000
Q1 2022 Apr 14, 2022	BUY	$29.88 - $37.04 $7,709 - $9,556	258 Added 60.99%	681 $25,000
Q4 2021 Feb 14, 2022	SELL	$25.61 - $35.1 $409 - $561	-16 Reduced 3.64%	423 $13,000
Q3 2021 Nov 10, 2021	BUY	$33.54 - $40.55 $10,665 - $12,894	318 Added 262.81%	439 $15,000
Q2 2021 Aug 04, 2021	SELL	$34.54 - $47.25 $932 - $1,275	-27 Reduced 18.24%	121 $5,000
Q4 2020 Feb 04, 2021	SELL	$45.3 - $60.27 $4,122 - $5,484	-91 Reduced 38.08%	148 $8,000
Q3 2020 Nov 09, 2020	BUY	$47.45 - $62.95 $2,087 - $2,769	44 Added 22.56%	239 $11,000
Q2 2020 Aug 06, 2020	BUY	$46.85 - $61.05 $3,326 - $4,334	71 Added 57.26%	195 $11,000
Q1 2020 May 12, 2020	SELL	$41.6 - $63.4 $3,369 - $5,135	-81 Reduced 39.51%	124 $6,000
Q3 2019 Nov 01, 2019	BUY	$59.06 - $72.15 $118 - $144	2 Added 0.99%	205 $12,000
Q2 2019 Aug 08, 2019	BUY	$62.09 - $86.14 $186 - $258	3 Added 1.5%	203 $13,000
Q1 2019 May 10, 2019	BUY	$52.92 - $81.17 $5,292 - $8,117	100 Added 100.0%	200 $16,000
Q2 2017 Aug 09, 2017	BUY	N/A	100	100 $5,000

403

136M

862K

582K

Ticker IONS
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 141,940,992
Market Cap $5.35B
Description
Ionis Pharmaceuticals, Inc. discovers and develops RNA-targeted therapeutics in the United States. The company offers SPINRAZA for spinal muscular atrophy (SMA) in pediatric and adult patients; TEGSEDI, an injection for the treatment of polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; and WAYLIVRA, a treatment for famil...

Get notified when there are updates to the investment portfolio of Glassman Wealth Services, based on Form 13F filings with the SEC.

Stay updated on Glassman Wealth Services with notifications on news.